# Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

> **NCT07008703** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 132 (estimated)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** Injection of humanized nerve growth factor (NGF) antibody

## Key facts

- **NCT ID:** NCT07008703
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07008703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07008703, "Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07008703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*